Retrophin Inc. (NASDAQ:RTRX)’s share price rose 1.4% during trading on Friday . The company traded as high as $18.90 and last traded at $18.35, with a volume of 98,019 shares changing hands. The stock had previously closed at $18.09.

RTRX has been the topic of a number of recent research reports. BMO Capital Markets initiated coverage on shares of Retrophin in a report on Monday, April 11th. They issued an “outperform” rating and a $25.00 target price on the stock. Leerink Swann reaffirmed a “buy” rating and issued a $4.00 target price on shares of Retrophin in a report on Tuesday, June 21st. Finally, Zacks Investment Research raised shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $17.00 target price on the stock in a report on Saturday, May 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.60.

The stock has a market cap of $677.77 million and a PE ratio of 9.62. The firm’s 50-day moving average price is $17.88 and its 200-day moving average price is $15.98.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.36. The company earned $29 million during the quarter, compared to analysts’ expectations of $31 million. During the same quarter in the prior year, the company earned ($0.18) EPS. The firm’s revenue was up 66.7% compared to the same quarter last year. Equities research analysts anticipate that Retrophin Inc. will post $0.08 earnings per share for the current year.

In other news, EVP Alvin Shih sold 8,750 shares of the stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total transaction of $155,312.50. Following the completion of the transaction, the executive vice president now directly owns 167,084 shares in the company, valued at approximately $2,965,741. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Several large investors have recently bought and sold shares of the stock. Turner Investments L.P. raised its stake in Retrophin by 61.6% in the fourth quarter. Turner Investments L.P. now owns 384,760 shares of the biopharmaceutical company’s stock valued at $7,422,000 after buying an additional 146,720 shares in the last quarter. Tekla Capital Management LLC purchased a new stake in Retrophin during the fourth quarter valued at about $6,365,000. Cornerstone Capital Management Holdings LLC. raised its stake in Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 85,521 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 1,129 shares in the last quarter.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.